Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial readout for Celcuity's gedatolisib could act as a positive catalyst for mutant-selective inhibitors such as RLAY's zovegalisib. Oppenheimer expects the VIKTORIA-1 results to fall short of expectations. He noted that anything below a “teenage” median progression-free survival for the gedatolisib triplet would establish a competitive benchmark that RLAY's zovegalisib-based regimen could surpass. Regarding Zovegalisib, Relay Therapeutics, Inc. (NASDAQ:RLAY) presented a subset of results from interim clinical data for the drug at the 2025 San Antonio Breast Cancer Symposium on December 12, 2025. Zovegalisib and fulvestrant together produced a median progression-free survival of 11.4 months in second-line patients in the ReDiscover first-in-human trial. Despite substantial prior treatment, efficacy was consistent across several p
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances [Yahoo! Finance]Yahoo! Finance
- Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism [Seeking Alpha]Seeking Alpha
- Celcuity Inc.: A Die To Be Cast Before July 2026 [Seeking Alpha]Seeking Alpha
- Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain [Yahoo! Finance]Yahoo! Finance
- Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 1/29/26 - Form 4
- 1/27/26 - Form 144
- 1/16/26 - Form SCHEDULE
- CELC's page on the SEC website